An Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma
| Registry | NCT00847366 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; non randomized, crossover, masking: none, treatment |
| Enrollment | 10 (Actual) |
| Sponsor | AEterna Zentaris (Industry) |
| Conditions | Non Small Cell Lung Cancer, Solid Tumors, Metastatic Breast Cancer, Sarcomas |
| Interventions | Perifosine, Trastuzumab, Tamoxifen (Drug) |
| Dates | start 2008-05-01, primary completion 2012-12-01, completion 2012-12-01, first posted 2009-02-19, last updated 2018-03-15 |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Non Small Cell Lung Cancer All trials for Solid Tumors All trials of Perifosine All trials of Trastuzumab
This is an open label trial for patients currently enrolled in other perifosine trials.
Perifosine is an oral anticancer agent with limited toxicity and a novel mechanism of action that is distinctly different from cytotoxic chemotherapies. It has been shown to inhibit and otherwise modify signaling through a number of pathways including Akt, p21, and JNK. Perifosine has been tested in Phase I and Phase II settings in a variety of dosing schedules including daily, weekly, and daily following a loading dose. In general, it has been well tolerated with dose-related nausea, vomiting, diarrhea, and fatigue being the most commonly observed toxicities.
Perifosine has induced partial responses or stable disease in solid tumors including but not limited to renal cell, sarcoma, and hepatocellular carcinoma. Perifosine is currently being studied in multiple diseases as a single agent as well as in combination with other cancer therapies. As studies are closed there are patients that have achieved a partial response or stable disease.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Perifosine 201 | Experimental | Drug: Perifosine | Perifosine 201: A Phase 1/2 trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer. Perifosine dosage: Arm A: 50 mg p.o. 3 times daily with meals. Arm B: 150 mg p.o. daily at bedtime. Arm C: 300 mg p.o. 3 times a day (900 mg) once a week. |
| Perifosine 206 | Experimental | Drug: Perifosine; Drug: Trastuzumab | Perifosine 206: A Randomized Phase II Trial of Three Doses of Perifosine in Combination with Trastuzumab. Arm A: Perifosine 50 mg p.o. daily + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle. Arm B: Perifosine 50 mg p.o three times a day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle. Arm C: Perifosine 300 mg three times on one day + 6 mg/kg Trastuzumab on day 1 of a 21-day cycle or 2 mg/kg on days 1, 8 and 15 of a 21 day cycle. |
| Perifosine 207 | Experimental | Drug: Perifosine | Perifosine 207: a Phase IIA Trial of Two Schedules of Perifosine Arm A: 50 mg daily with food. Arm B: 50 mg twice daily with food. |
| Perifosine 208 | Experimental | Drug: Perifosine; Drug: Tamoxifen | Perifosine 208: A Phase II Trial of Two Schedules of Perifosine in Combination with Endocrine Therapy (Tamoxifen) for Patients with Estrogen Receptor or Progesterone Receptor Positive Metastatic Breast Cancer Dosage: Arm A: 50 mg Perifosine /day p.o. .Endocrine therapy continued at same dose and schedule. Arm B: 900 Perifosine weekly. Endocrine therapy continued at same dose and schedule. |
| Perifosine 209 | Experimental | Drug: Perifosine | Perifosine 209: A Phase II Trial of Perifosine in Patients with Sarcomas. Perifosine 900 mg weekly (This dose should be divided so that the maximum dose rate is 300 mg in any 4-hour interval). |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Patients must be currently receiving treatment with perifosine on a previously approved protocol. * Patients must have had at least one evaluation following the initiation of treatment and have stable disease, partial response or complete response. * Patient is willing to sign a new consent Regarding the protocol no exclusion criteria are described.